CN110840909A - Medical application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis - Google Patents
Medical application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis Download PDFInfo
- Publication number
- CN110840909A CN110840909A CN201911265600.XA CN201911265600A CN110840909A CN 110840909 A CN110840909 A CN 110840909A CN 201911265600 A CN201911265600 A CN 201911265600A CN 110840909 A CN110840909 A CN 110840909A
- Authority
- CN
- China
- Prior art keywords
- astragalus polysaccharide
- preventing
- leptospira
- astragalus
- leptospirosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The invention provides a medical application of astragalus polysaccharide in preparation of a medicine for preventing and treating leptospirosis. In the invention, the astragalus polysaccharide standard substance is adopted, and the astragalus polysaccharide is injected into golden yellow hamster sensitive to leptospira in advance at the dose of 50mg/kg, so that the infection of the leptospira can be effectively controlled after 2X108/ml of leptospira is infected, and the survival rate is 100 percent. The invention expands the medicinal range of the astragalus polysaccharide and provides a basis for the development of new application of the astragalus polysaccharide.
Description
Technical Field
The invention provides a new medical application of astragalus polysaccharide, in particular discloses an application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis, and belongs to the technical field of medicines.
Background
Leptospirosis (Leptospirosis) is a worldwide common zoonotic disease, called Leptospirosis for short, that is associated with occupational or living contacts and with exposure to leptospira, and is highly prevalent in flood-prone areas, and is particularly widespread in developing countries and tropical regions. The disease is susceptible to human and livestock, and the clinical manifestations after infection are various, so that diagnosis is not easy. The pathogen of the leptospirosis can continuously exist in the host, further spread to pollute the environment, infect other people and animals, and cause serious harm. Currently, the methods for preventing and treating leptospira are the injection of vaccines and the use of antibiotics.
The Astragalus polysaccharides are water-soluble heteropolysaccharides obtained by extracting, concentrating and purifying dried root of Astragalus mongholicus (Fisch.) bge or Astragalus membranaceus (Fisch.) bge of Leguminosae, and have light yellow color, fine powder, uniformity, no impurities and hygroscopicity. The Astragalus polysaccharides comprises hexuronic acid, glucose, fructose, rhamnose, arabinose, galacturonic acid and glucuronic acid, can be used as immunopotentiator or regulator, and has antiviral, antitumor, antiaging, radioprotective, anti-stress, and antioxidant effects. However, there are few reports on the prevention and treatment of leptospira.
Disclosure of Invention
The invention aims to provide application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis, including prevention of leptospirosis and treatment after infection. The application of the astragalus polysaccharide can reduce the abuse of antibiotics and can also effectively prevent and control leptospira outbreak.
The invention aims to provide medical application of astragalus polysaccharide in preventing and treating leptospirosis, which comprises the prevention of leptospirosis and the treatment after infection.
The astragalus polysaccharide is used as a medicine for preventing and treating leptospirosis.
The astragalus polysaccharide is used as a medicine for preventing and treating leptospira and is suitable for any pharmaceutically acceptable carrier.
The pharmaceutical preparation is a standard astragalus polysaccharide liquid preparation, and the astragalus polysaccharide powder is dissolved and diluted by normal saline according to the dosage, wherein the dosage is 5mg/ml, and the dosage of the astragalus polysaccharide is 10 mg/kg.
The astragalus polysaccharide can effectively control the infection of leptospira, reduce the inflammatory reaction of each organ and improve the survival rate of golden hamster to 100 percent.
The invention has the positive effects that:
provides a new medical application of astragalus polysaccharide in preparing a medicament for preventing and treating leptospira; carrying out secondary development on the pharmacological action of the compound; the medicinal range of the astragalus polysaccharide is expanded; the invention can effectively reduce the use of antibiotics when treating and preventing leptospirosis, can also effectively prevent and control leptospirosis during outbreak, and has great effect on the healthy development of animal husbandry.
Description of the drawings:
FIG. 1 shows the resistance of golden hamster to Leptospira infection after injection of Astragalus polysaccharides;
FIG. 2 shows the effect of Astragalus polysaccharides on the removal of leptospira in the body;
FIG. 3 shows the protective effect of Astragalus polysaccharides on the major organs of golden hamster;
FIG. 4 shows that Astragalus polysaccharides cause the expression level of important inflammatory factors in the body.
The specific implementation mode is as follows:
the present invention is further illustrated by the following examples, which do not limit the present invention in any way, and any modifications or changes that can be easily made by a person skilled in the art to the present invention will fall within the scope of the claims of the present invention without departing from the technical solution of the present invention.
Example 1
The astragalus polysaccharide is used as a medicine for preventing and treating leptospirosis.
Example 2
The astragalus polysaccharide as the medicine for preventing and treating leptospira is suitable for any pharmaceutically acceptable carrier.
Example 3
The pharmaceutical preparation is a liquid preparation of astragalus polysaccharide standard substance, and the astragalus polysaccharide powder is dissolved and diluted by normal saline according to the dosage.
Example 4
The pharmaceutical preparation is a standard astragalus polysaccharide liquid preparation, and the astragalus polysaccharide powder is dissolved and diluted by normal saline according to the dosage, wherein the dosage is 5mg/ml, and the dosage of the astragalus polysaccharide is 10 mg/kg.
Test example 1
The Astragalus polysaccharides has effects of preventing leptospira infection.
Experimental drugs:
the astragalus polysaccharide standard substance is diluted by normal saline at 5mg/ml, and is injected subcutaneously at a dose of 50mg/kg according to the body weight of golden hamster.
The experimental method comprises the following steps:
the experiment was divided into two groups, i.e., an experimental group and a control group, each of eight four-week-old golden hamster. The experimental group was injected with astragalus polysaccharides at a dose according to body weight one week before infection, and the control group was injected with physiological saline. One week later, 2X10 was intraperitoneally injected8The leptospira of (1). And observing the survival rate.
The experimental results are as follows:
referring to fig. 1, the survival rate of the experimental group injected with astragalan was 100%, while all of the golden hamster of the control group died. Therefore, the astragalus polysaccharide can effectively prevent the infection of leptospira.
Test example 2
Scavenging effect of astragalus polysaccharide on leptospira in organism
The experimental method comprises the following steps:
the golden hamster of the control group and the experimental group in example 1 was sampled, and the liver, kidney and lung of each group of golden hamster were collected, and subjected to DNA extraction of leptospira in the tissue, followed by a fluorescent quantitative PCR experiment to analyze the load of leptospira in each organ of golden hamster.
The experimental results are as follows:
referring to fig. 2, compared to the control group injected with physiological saline only, the mice injected with astragalan have a significant decrease in the leptospira loading in liver, kidney and lung.
Test example 3
The golden hamster of the control group and the golden hamster of the experimental group in example 1 was sampled from the liver, kidney and lung to prepare a pathological section, and then HE staining was performed. Observation was performed under an optical microscope at 100X.
The experimental results are as follows:
referring to fig. 3, the liver, kidney and lung of golden-yellow hamster in the control group all had bleeding and inflammatory lesions of different degrees (a, b and c are liver, kidney and lung of control group), while the pathological changes of liver, kidney and lung of golden-yellow hamster in the experimental group were not particularly obvious, and there were no bleeding spots and inflammatory lesions (d, e and f are liver, kidney and lung of experimental group).
Test example 4
The control and experimental golden hamster of example 1 were sampled from liver, kidney and lung, and RNA was extracted from these tissues, and Tlr2, Tlr4, IL- β, IL-6 and IL-10 were assayed by fluorescent quantitative PCR and observed for expression at 2d and 5 d.
The experimental results are as follows:
referring to FIG. 4, compared with the control group, the mRNA expression of TLR2, Tlr4, IL-1 β, IL-6 and IL-10 in liver and kidney was significantly higher at 2dpi and lower at 5 dpi in the experimental group injected with Astragalus polysaccharides, although the difference between Tlr4 and IL-6 in kidney was not significant at 2dpi, the combined results showed that 2dpi after bacterial attack of Astragalus polysaccharides led to the early arrival of inflammatory storm and the decrease at 5 dpi, which resulted in the protective effect on golden hamster.
Claims (3)
1. The astragalus polysaccharide is used for preparing medicines for preventing and treating leptospirosis.
2. The astragalus polysaccharide used as the medicine for preventing and treating leptospira is applicable to any pharmaceutically acceptable carrier.
3. The pharmaceutical preparation is a liquid preparation of astragalus polysaccharide standard substance, β -glucan powder is dissolved and diluted by normal saline according to the dosage, 5mg/ml, and the dosage of β -glucan is 10 mg/kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911265600.XA CN110840909A (en) | 2019-12-11 | 2019-12-11 | Medical application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911265600.XA CN110840909A (en) | 2019-12-11 | 2019-12-11 | Medical application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110840909A true CN110840909A (en) | 2020-02-28 |
Family
ID=69608627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911265600.XA Pending CN110840909A (en) | 2019-12-11 | 2019-12-11 | Medical application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110840909A (en) |
-
2019
- 2019-12-11 CN CN201911265600.XA patent/CN110840909A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 熊东艳等: "浅谈犬钩端螺旋体病的诊治", 《北京农业》 * |
| 陆松兵，等: "猪钩端螺旋体病诊治", 《畜禽业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7125836B2 (en) | Method of cancer screening; method of cancer treatment; and method of diabetes treatment | |
| CN104352457A (en) | Chlorogenic acid crystal form-containing preparation and application thereof | |
| CN109045035B (en) | Application of 7- (2, 2-dimethyl-3-butenamido) -octahydro phenylquinoline acetate in preparation of medicine for treating liver diseases | |
| CN110840909A (en) | Medical application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis | |
| CN111228287A (en) | Application of epimedium flavone glycoside compound in preparing medicine for treating melanoma | |
| CN1169839C (en) | Wolfberry polysaccharide and its prepn. and application | |
| CN1201737C (en) | Application of cepharanthine in preparing medicine for resisting SARS virus | |
| CN110772528B (en) | Application of iris polysaccharide as medicine in preparing medicine for preventing and treating leptospirosis | |
| CN101632726B (en) | Application of Chinese medicinal composition in preparing medicament for treating blood vessel micro-embolization | |
| CN111249266B (en) | Application of peramivir in preparation of medicine for treating inflammatory storm caused by infectious diseases | |
| CN104998277B (en) | A kind of resisting toxoplasmosis prescription medicine and its screening technique | |
| CN108888628B (en) | Application of ginsenoside GRh2 in preparing anti-toxoplasma gondii compound preparation and medicine thereof | |
| CN109662968A (en) | The liter white preparation of -5 α androstane hydride compounds of carbon loss containing A- and its application | |
| CN1064235C (en) | Pharmaceutical application of glucoside A and B of auricledleaf swallowort | |
| CN110787182A (en) | β medical application of dextran in preventing and treating leptospirosis | |
| CN1068790C (en) | Medicinal composition containing total saponin extracted from stem and leaves of American ginseng | |
| CN104224857B (en) | A kind of Hericium erinaceus hypha extract is preparing the application in resisting straight colon cancer drug | |
| CN113827604B (en) | Application of adefovir in preparing medicine for treating tumor or resisting tumor metastasis | |
| CN104224856B (en) | Hericium erinaceus mycelium extract and application thereof in preparation of head-neck cancer resistant drugs | |
| US20060099172A1 (en) | Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of prophylaxis and treatment of avian influenza | |
| CN100349589C (en) | Medical application of rehmannia root extractive in resisting asthma and allergy | |
| CN113116906A (en) | Application of cycloastragenol in preparation of medicine for preventing and treating chronic bronchitis | |
| CN114903933A (en) | Traditional Chinese medicine for treating eperythrozoonosis of sheep and preparation method and application thereof | |
| CN114053253A (en) | Chlorobenzidine hydrochloride, combined medicine thereof and application of chlorobenzene guanidine hydrochloride in treating babesiosis | |
| CN1569015A (en) | Application of saponins in the preparing process of coxsackie virus resisting medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200228 |
|
| WD01 | Invention patent application deemed withdrawn after publication |